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A B S T R A C T
Iodide ions (I−) are an essential dietary mineral, and crucial for mental and physical development, fertility and
thyroid function. I− is also a high aﬃnity substrate for the heme enzyme myeloperoxidase (MPO), which is
involved in bacterial cell killing during the immune response, and also host tissue damage during inﬂammation.
In the presence of H2O2 and Cl−, MPO generates the powerful oxidant hypochlorous acid (HOCl), with excessive
formation of this species linked to multiple inﬂammatory diseases. In this study, we have examined the hy-
pothesis that elevated levels of I− would decrease HOCl formation and thereby protein damage induced by a
MPO/Cl−/H2O2 system, by acting as a competitive substrate. The presence of increasing I− concentrations
(0.1–10 μM; i.e. within the range readily achievable by oral supplementation in humans), decreased damage to
both model proteins and extracellular matrix components as assessed by gross structural changes (SDS-PAGE),
antibody recognition of parent and modiﬁed protein epitopes (ELISA), and quantiﬁcation of both parent amino
acid loss (UPLC) and formation of the HOCl-biomarker 3-chlorotyrosine (LC-MS) (reduced by ca. 50% at 10 μM
I−). Elevated levels of I− ( > 1 μM) also protected against functional changes as assessed by a decreased loss of
adhesion (eg. 40% vs.< 22% with> 1 μM I−) of primary human coronary artery endothelial cells (HCAECs), to
MPO-modiﬁed human plasma ﬁbronectin. These data indicate that low micromolar concentrations of I−, which
can be readily achieved in humans and are readily tolerated, may aﬀord protection against cell and tissue
damage induced by MPO.
1. Introduction
Iodide (I−) is an essential dietary mineral which plays a key role in
thyroid function [1], where it is the major substrate for the heme en-
zyme thyroid peroxidase (also known as thyroperoxidase or iodide
peroxidase), which generates the key hormones triiodothyronine (T3)
and thyroxine (T4), from tyrosine (Tyr) residues present on thyr-
oglobulin. I− deﬁciency results in hypothyroidism, impaired mental
and physical development, decreased fertility rate, and goiter [2].
While there are risks associated with excess consumption, I− supple-
mentation represents a simple, cheap and highly beneﬁcial health in-
tervention [3].
I− is also a substrate for other mammalian heme peroxidases, in-
cluding myeloperoxidase (MPO), a key enzyme released from
intracellular storage granules of activated neutrophils, monocytes and
some tissue macrophages, as part of innate immune defence against
invading pathogens [4,5]. MPO generates the highly reactive and da-
maging oxidant hypochlorous acid (HOCl) from hydrogen peroxide
(H2O2) and chloride ions (Cl−) in order to kill bacteria, yeast and other
foreign materials, and low levels of MPO are known to be associated
with chronic infections [4,5]. However, MPO can also oxidize other
anions (e.g. Br−, SCN−, I−, NO2−) as well as organic substrates [4,6,7].
Inappropriate production of HOCl and other oxidizing species by
MPO (e.g. via sterile inﬂammation, excessive or inappropriate stimu-
lation of the immune system) has been linked to a number of human
inﬂammatory pathologies, including cardiovascular diseases, cystic ﬁ-
brosis, asthma, kidney disease and a number of degenerative neurolo-
gical conditions including Parkinson's and Alzheimer's diseases,
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amongst others [4,5,8–11]. MPO is released extracellularly (i.e. into
phagolysosomes or externally to the cell), and is known to bind avidly
to negatively-charged macromolecules including proteins, proteogly-
cans and glycosaminoglycans of the extracellular matrix (ECM) [12,13].
HOCl reacts with high rate constants with biological targets, and par-
ticularly proteins [14,15], and would therefore not be expected to
diﬀuse large distances from its site of generation [16]. This is likely to
result in marked damage to ECM materials to which it is bound, or
those in close proximity. Considerable data support this hypothesis,
with extensive damage detected on ECM materials at sites of in-
ﬂammation, including within the artery wall during the development of
atherosclerosis [17]. Thus up to 70% of the oxidized proteins detected
in human atherosclerotic lesions has been reported to be ECM derived
[18], and considerable evidence also exists for modiﬁcation of other
extracellular materials including plasma proteins, and low- and high-
density lipoproteins [19–22]. The ECM plays a critical role as the major
load-bearing and structural component of tissues and is also a key de-
terminant of cell binding, proliferation and migration, a reservoir for
growth factors and cytokines, and a major modulator of enzyme activity
and function [23,24]. Evidence has been presented for the presence of
MPO mRNA, protein and enzymatic activity in cardiovascular lesions,
together with evidence for protein damage and a strong association
between the extent of HOCl-mediated damage and the severity of dis-
ease [8,25–27]. The detection of MPO in the shoulder regions of
atherosclerotic lesions, which are susceptible to rupture (the major
cause of many heart attacks and strokes) indicates that the damage
induced by this enzyme may play a major role in such events [28,29].
Furthermore, strong associations have been reported between the levels
of MPO and the diagnosis and severity of cardiovascular disease, with
the levels of this enzyme being both diagnostic of the disease, and
prognostic of adverse outcomes [30–32]. Consistent with these data,
recent work has highlighted the potential of molecular imaging of MPO
in determining high-risk atherosclerotic plaques [33,34].
Modulation of MPO activity have been proposed as a therapeutic
approach in inﬂammatory diseases, as inhibition may reduce MPO-de-
rived oxidative damage [35]. Thus both suicide and competitive in-
hibitors of MPO (e.g. benzoic acid hydrazides [36] and thioxanthines
[37]), and alternative substrates (e.g. nitroxides [38], acetaminophen/
paracetamol [39]) have been examined as potential modulators of
MPO-derived damage (reviewed [10,40]). Whilst Cl− is the most
abundant MPO substrate, its oxidation by Compound I is relatively slow
compared to Br−, I−, and SCN− with apparent second order rate
constants, at pH 7.0, of 2.5× 104, 1.1× 106, 7.2× 106, and
9.6×106M−1 s−1 for Cl−, Br−, I− and SCN− respectively [7]. Oxi-
dation of SCN− generates hypothiocyanous acid (HOSCN) [41]. HOSCN
is a less powerful and less reactive oxidant than HOCl, with a high
speciﬁcity for thiols (RSH, both free and in proteins), though these
reactions occur at modest rates (k ~104 vs ~108M−1 s−1 for reaction
of Cys with HOSCN and HOCl, respectively) [42]. Increasing the con-
centration of SCN− alters the ratio of HOCl to HOSCN formed by MPO,
and can decrease biological damage [41,43,44]. SCN− supplementation
(via drinking water) of mice that express human MPO decreases the size
of atherosclerotic lesions present in their arteries when fed a high-fat,
high-cholesterol diet [45]. In addition, a retrospective analysis of
people who suﬀered a ﬁrst myocardial infarction with a subsequent 12
year follow-up, indicated that the lowest rates of subsequent all-cause
mortality were in the group with low MPO levels and high SCN−, and
that high levels of SCN− were associated with decreased mortality [46].
The extent of this eﬀect cannot be ascertained completely, as this po-
pulation contained both non-smokers, as well as ex- and current smo-
kers, with the smokers have a known and signiﬁcantly elevated risk of
cardiovascular disease. However, despite this confounding factor,
consideration of the data as a whole indicates that increasing SCN−
levels in vivo may aﬀord protection against the development or pro-
gression of atherosclerosis.
Oxidation of I− by Compound I of MPO is only marginally slower
than for SCN−, and the resulting hypoiodous acid (HOI) has a much
lower redox potential than HOCl (0.78 vs 1.28 V). Thus HOI would be
expected to be both selective and less damaging than HOCl [47]. Sev-
eral experimental and epidemiological studies have provided evidence
for a protective eﬀect of I− in cardiovascular disease, but the under-
lying biochemical mechanism(s) are unclear [48]. Low urinary I−
concentrations have been associated with coronary artery disease in the
North American National Health and Nutrition Examination Study
(NHANES) [49], and recent work has shown that I− can protect heart
tissue against reperfusion injury-induced damage in a murine model
[50]. This has been proposed to be due to metabolic changes [50], but
MPO has also been strongly associated with reperfusion induced tissue
injury as a result of neutrophil accumulation and activation after O2
deprivation [51]. A role for I− in modulating MPO-induced damage has
poorly studied probably as a result of its low systemic concentration
( < 1 μM for I−, 100mM for Cl−, 20–80 μM for SCN−) [52], though
there is abundant evidence that I− levels can be signiﬁcantly elevated
by interventions [53,54]. In the light of these data, we hypothesised
that I− might reduce oxidative damage induced by MPO, when I− le-
vels are elevated over typical physiologic levels. Here we provide evi-
dence in support of this hypothesis, with increased I− concentrations
modulating protein damage induced by MPO. These ﬁndings illustrate
the potential of I− to minimize damage associated with MPO-mediated
damage and chronic inﬂammation.
2. Materials and methods
2.1. Chemicals and reagents
Unless otherwise stated, all chemicals were purchased from com-
mercial sources and used as received. UPLC buﬀers were prepared using
HPLC grade methanol (VWR) and tetrahydrofuran (Chromasolv Plus,
Sigma Aldrich). Aqueous solutions were prepared using MilliQ water
and buﬀers were prepared from 0.5M sodium phosphate buﬀer at pH
7.4, or PBS, and chelex-treated prior to use to remove trace metal ions.
Cl− and I− solutions were prepared using NaCl and KI (Sigma Aldrich).
The concentration of stock H2O2 and HOCl solutions (Sigma Aldrich)
were determined spectrophotometrically (H2O2 in H2O, ε240
43.6 M−1 cm−1; HOCl in 0.5 M NaOH, ε292 350M−1 cm−1).
Immunoblotting and ELISA were performed using the following
monoclonal antibodies (mAb): anti-ﬁbronectin A17 (ab26245, Abcam),
anti-ﬁbronectin A32 (CSI 005-32-02, Thermo Fisher Scientiﬁc),
2D10G9 (raised against HOCl-modiﬁed protein; a kind gift from A. Prof
Ernst Malle, Medical University of Graz, Austria) and anti-dityrosine
(Clone 1C3 monoclonal antibody, Nordic Biosite) [55]. Detection of
immune complexes from immunoblotting was achieved with ECL anti-
rabbit IgG horseradish peroxidase-linked whole antibody (NA934V, GE
Healthcare UK). Detection for ELISA was achieved with a polyclonal
rabbit anti-mouse IgG alkaline phosphate conjugated antibody
(ab97043, Abcam).
2.2. Treatment of ﬁbronectin with HOCl or MPO/H2O2/Cl− system in the
presence of I−
Human plasma ﬁbronectin (0.228 μM ﬁnal concentration for SDS-
PAGE and immunoblotting, 1.14 μM for HPLC analysis) was diluted in
phosphate buﬀer (0.1M ﬁnal concentration, pH 7.4) containing Cl−
(0.1M) and I− over the concentration range 0.01–400 μM. For the
MPO/H2O2 system, a 500-fold molar excess of H2O2 over the enzyme
concentration, was added in ﬁve equal aliquots to samples containing
100 nM MPO over a period of 10min and incubated for 2 h at 37 °C.
2.3. Ultra high-performance liquid chromatography (UPLC)
Loss of parent amino acids was quantiﬁed by UPLC analysis with
pre-column derivatization using o-phthaldialdehyde. Fibronectin
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samples (25 μg of protein in 50 μL 0.1M phosphate buﬀer) were hy-
drolysed using 4M methanesulfonic acid as described previously [56],
with minor modiﬁcations. Proteins were precipitated by the addition of
150 μL 10.67% (w/v) trichloroacetic acid and incubated at 4 °C for
15min. After removal of the supernatant, the protein pellet was hy-
drolysed by the addition of 50 μL 4M MSA containing 0.2% (w/v)
tryptamine (Sigma Aldrich) and incubation for 16 h under vacuum at
110 °C. The samples were then neutralised with 55 μL freshly prepared
4M NaOH, ﬁltered using Nanosep MF 0.2 μm centrifugal ﬁlters and
diluted 10-fold with 0.2 M aqueous sodium carbonate buﬀer, pH 10.3.
Pre-column derivatization of the diluted samples (40 μL) was performed
with OPA (40 μL, 1mgmL−1 in 0.2M aqueous sodium carbonate buﬀer
pH 10.3, with 1 μLmL−1 2-mercaptoethanol added prior to derivati-
zation). Standard curves were generated using commercially-available
amino acid mixtures. The ﬂuorescently tagged amino acid derivatives
were separated on a Shimadzu Nexera system using a Kinetex 2.6 μm
EVO C18 100 Å LC column (150× 3.0mm) and eluted using a gradient
system (Buﬀer A: 100mM sodium acetate, pH 5.3 in water with 2.5%
(v/v) tetrahydrofuran and 15% (v/v) methanol; Buﬀer B: 100mM so-
dium acetate pH 5.3 in water with 2.5% (v/v) tetrahydrofuran and 80%
(v/v) methanol). A ﬂow rate of 0.8 mLmin−1 was used, with the fol-
lowing gradient: 100% buﬀer A for 3min, 0–10.5% buﬀer B linear
gradient over 7.5 min, 10.5% buﬀer B for 5min, 10.5–65% buﬀer B
linear gradient over 3min, 65–100% buﬀer B linear gradient over
1min, 100% buﬀer B for 2min, 100-0% buﬀer B linear gradient over
0.5 min, followed by equilibration at 100% buﬀer A for 3.5 min. The
tagged amino acids were detected using a Shimadzu RF-20A ﬂuores-
cence detector with λex 340 nm and λem 440 nm.
2.4. SDS-PAGE and immunoblotting
Samples for SDS-PAGE analysis were prepared using NuPAGE LDS
Sample Buﬀer (4x dilution) and NuPAGE Sample Reducing Agent (10x
dilution) according to the manufacturer's instructions (Invitrogen).
Protein samples were denatured by incubation at 70 °C for 10min.
Proteins were loaded at 0.5 μg per well for 12-well gels, and 0.375 μg
per well for 15-well gels. HiMark™ pre-stained protein standards
(31–460 kDa) were used as molecular mass markers. Electrophoresis
was carried out on 1mm NuPAGE NOVEX 3–8% Tris-Acetate Gels using
NuPAGE Tris-Acetate SDS Running Buﬀer at 150 V for 70min.
Following electrophoretic separation, proteins were analysed using
immunoblotting.
For immunoblotting, proteins were electroblotted onto PVDF
membranes over a period of 7min using an iBlot® transfer apparatus
(Invitrogen). The membranes were blocked with 1% (w/v) BSA in TBS
with Tween 20 (TBST) for 1 h and then incubated with primary anti-
body (A17, 1:10,000 and anti-dityrosine, 1:500) in blocking solution
overnight at 4 °C. Membranes were then rinsed 3 times with TBST for
5min before incubation with secondary HRP-conjugated antibody.
Unbound antibody was removed by 4 washes with TBST for 10min, and
once with TBS for 10min. Immune complexes were detected using
Western Lightning Plus ECL reagent (NEL104001EA; Perkin Elmer,
Waltham, MA, USA) and imaged using a G: BOX Chemi XR5 system
(Syngene).
2.5. ELISA based analysis of loss of parent ﬁbronectin epitopes and HOCl-
mediated protein damage
Human plasma ﬁbronectin (50 μL per well, 5 μgmL−1 in 0.1 M
phosphate buﬀer, pH 7.4) was coated onto 96-well high-binding mi-
crotitre plates by incubation overnight at 4 °C. The wells were then
washed twice with 200 μL PBS to remove any excess or non-bound ﬁ-
bronectin, then treated with MPO (20 nM), H2O2 (32 μM), Cl−
(100mM) and varying concentrations of I− in a total volume of 50 μL
0.1 M phosphate buﬀer, pH 7.4. After incubation at 37 °C for 2 h, the
wells were washed twice with 200 μL PBS and blocked with 100 μL
0.1% casein (w/v) in PBS for 1 h at 21 °C. The wells were then washed
twice with 200 μL PBS and incubated with 50 μL primary antibody
(diluted in 0.1% casein (w/v) in PBS; A17 1:25,000, A32 1:2000,
2D10G9 1:100) overnight at 4 °C. Unbound antibody was removed by
two washes with 200 μL PBST, and the wells were then incubated with
50 μL secondary antibody (Alkaline Phosphatase conjugated anti-mouse
Ig in 0.1% casein (w/v) in PBS; 1:1000) for 1 h at 21 °C. Unbound
secondary antibody was then removed by four washes with 200 μL
TBST. TBST was employed for the ﬁnal washes to avoid interference of
phosphate in the Alkaline Phosphatase assay, in which 50 μL of Alkaline
Phosphatase Yellow (p-nitrophenylphosphate, pNPP) substrate solution
(Sigma Aldrich) was added to each well and the absorbance measured
at 405 nm using a microplate reader (SpectraMax i3x Multi-Mode
reader).
2.6. Determination of 3-chloro-L-tyrosine by LC-MS
Protein samples (25 μg) were precipitated with TCA (8% w/v ﬁnal
concentration) and spiked with isotope-labelled 3-chloro-[13C6]tyrosine
(100 pmol) before evaporation using a centrifugal vacuum concentrator
for 1 h at 60 °C. The protein pellet was hydrolysed overnight in 4M
methanesulfonic acid (50 μL) under vacuum at 110 °C. The resulting
liberated amino acids were partially puriﬁed by solid-phase extraction
using 1mL C-18 cartridges (Supelco), with the columns activated using
100% methanol (1 mL), followed by equilibration with 0.1% TFA in
water (2× 1mL). Samples were diluted with 1% TFA in water (10 μL
hydrolysate into 400 μL of 1% TFA) in order to improve ion-pairing and
subsequent binding of amino acids to the C18 material. The samples
were loaded onto the column and washed with 0.1% TFA in water
(1×1mL) followed by elution with 50% methanol containing 0.1%
formic acid (1× 1mL). Extracts were dried at 60 °C under vacuum for
4 h and then redissolved in 50 μL 0.1% formic acid.
3-Chlorotyrosine (3-ClTyr) was quantiﬁed by ESI LC-MS in the po-
sitive ion mode using a Bruker Impact HD II mass spectrometer.
Samples were separated by gradient elution using a Phenomenex Aeris™
2.6 μm PEPTIDE XB-C18 250×2.1mm HPLC column. The elution was
initiated at 3% B for 1min, followed by gradient elution from 3 to 50%
B over 9min, 50–80% B over 2min, followed by isocratic elution using
80% B for 3min, before decreasing to 3% B over 2min and re-equili-
bration at 3% B for 3min. Buﬀer A consisted of 0.1% formic acid in
H2O, and buﬀer B 80% acetonitrile in H2O with 0.1% formic acid. The
electrospray needle was held at 4500 V, with end plate oﬀset of 500 V
and temperature of 200 °C. Nitrogen gas was used for both the nebuliser
(2.0 Bar) and as the dry gas (8.0 Lmin−1). An external standard curve
was generated for 3-ClTyr with 78 fmol–20 pmol loaded onto the
column, with the internal standard maintained at a loading of 4 pmol. A
linear response of 3-ClTyr relative to the internal standard was ob-
served over this concentration range. Standards were prepared in 0.1%
formic acid in H2O. Spectra were collected in MS1 mode and quanti-
ﬁcation performed on extracted ion chromatograms for 3-ClTyr (m/z
216.04) and 3-chloro-[13C6]tyrosine (m/z 222.06).
2.7. Determination of H2O2 consumption by MPO
Consumption of H2O2 by MPO was determined in the presence of
Cl− and varying amounts of I− using an H2O2-sensitive electrode
(World Precision Instruments, HPO-ISO-2), as reported previously [38].
Solutions were prepared using 0.1M sodium phosphate buﬀer, pH 7.4,
with 50 μMH2O2 added, followed by 20 nM MPO. Methionine (250 μM)
was included to quench the HOCl formed and prevent loss of enzyme
activity. The removal of H2O2 was monitored until complete con-
sumption. The rate of turnover was determined by using the initial
linear sections of the H2O2 consumption curves, over a period of 120 s,
after stabilization of the signal following MPO injection.
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2.8. Cell adhesion centrifugation assay
Human plasma ﬁbronectin (50 μL per well, 10 μgmL−1 in 0.1 M
phosphate buﬀer at pH 7.4) was coated onto a 96-well tissue-culture
treated, clear-bottom, black well plates by incubation overnight at 4 °C.
The wells were washed twice with 200 μL PBS to remove excess or non-
bound ﬁbronectin, then treated with MPO (20 nM), H2O2 (64 μM), Cl−
(100mM) and varying concentrations of I− in a total volume of 50 μL
0.1 M phosphate buﬀer, pH 7.4. Following incubation at 37 °C for 2 h,
the wells were washed twice with 200 μL DPBS and blocked for
30min at 21 °C with 100 μL BSA in DPBS (1% w/v, heat-denatured at
85 °C for 12min, sterile-ﬁltered). The wells were then washed twice
with 200 μL DPBS to remove blocking solution, and human coronary
artery endothelial cells added (Cell Applications, San Diego, CA, USA;
20,000 cells well−1 in 50 μL basal media, pre-loaded with Calcein-AM
at 5 μM in basal media for 30min). The cells were allowed to adhere for
2 h in an incubator at 37 °C. The wells were then overﬁlled with HBSS
(with Mg2+/Ca2+), sealed with adhesive foil and placed upside down
in a centrifuge. The plate was centrifuged at 40 g for 5min followed by
removal of the supernatant containing unbound cells by inversion of the
plate. Relative cell density was obtained by measurement of Calcein-
AM ﬂuorescence (λex 485 nm, λem 525 nm) using a microplate-reader
(SpectraMax i3x Multi-Mode reader, 12-point measurement, average of
4 technical replicates).
2.9. Determination of iodate as generated by the MPO/H2O2/Cl− system
Iodate was quantiﬁed by reaction with an excess of KI in H2SO4/
H3BO3 via the Villermaux-Dushman reaction (iodate/iodide variation
of the iodine-clock reaction) [57]. Brieﬂy, MPO (20 nM) was reacted
with H2O2 (64 μM) in the presence of Cl− (100mM) and varying con-
centrations of I− in a total volume of 1mL 0.1M phosphate buﬀer, pH
7.4. Reactions were performed with, or without, BSA (50 nM) as a
scavenger for generated HOCl/HOI. Following incubation at 37 °C for
2 h, the solutions were passed through a C18 cartridge to remove en-
zyme/protein (Supelco) and acidiﬁed by addition of 0.2MH2SO4 (2:1,
sample:H2SO4). IO3− in the solution was then determined spectro-
photometrically as I2 at 288 nm by reaction with KI (60mM) in a so-
lution of aqueous H3BO3 (100mM). A standard curve was prepared
with KIO3 at concentrations of 5–100 μM. Reactions were performed in
triplicate.
2.10. Determination of chloramines as generated by the MPO/H2O2/Cl−
system
The presence of chloramines generated by MPO was determined
using a TNB assay [56]. Brieﬂy, taurine (40mM) was incubated at 37 °C
for 30min with varying concentrations of IO3− (0–40 μM) and an
MPO/H2O2/Cl− system. Reactions were performed in the presence of
0.1 M sodium phosphate buﬀer at pH 7.4, MPO (100 nM), Cl−
(100mM) and H2O2 (50 μM). The reaction was stopped by addition of
catalase and chloramines determined by reaction with TNB (generated
from hydrolysis of DTNB in 50mM NaOH) and consumption of TNB
measured using a microplate-reader (ε412nm=14,150M−1 cm−1).
2.11. Statistical analysis
Experiments were performed as independent triplicates, unless
otherwise indicated, and errors are presented as standard deviation of
the mean. Statistical analyses were performed using GraphPad Prism 7
for Mac (GraphPad Software, San Diego, CA, USA) with p < 0.05 taken
as signiﬁcant. One-way analysis of variance (ANOVA) with Dunnett's
post hoc test was used to compare the eﬀects of MPO/Cl−/H2O2 treated
samples to the control (no I−) and the subsequent eﬀect of increasing
I− concentrations. Student's t-tests were used to compare untreated
samples with the control treatment (no I−).
3. Results
3.1. I− protects against damage to functional regions of human ﬁbronectin
induced by MPO/Cl−/H2O2
Exposure of human ﬁbronectin to increasing concentrations of HOCl
has been shown previously to result in chlorination of tyrosine (Tyr)
residues and oxidation at cysteine (Cys), methionine (Met) and tryp-
tophan (Trp) residues [58,59]. The eﬀect of I− on these modiﬁcations
was therefore examined in reaction systems in which human plasma
ﬁbronectin (0.228 μM) was exposed to MPO (100 nM)/H2O2 (50 μM)/
Cl− (100mM) using a microplate-based ELISA method to examine al-
terations to functional epitopes on the protein.
In the absence of I−, a signiﬁcant loss of epitope recognition of both
the cell binding region (mAb A17, 38.3 ± 5.6% loss versus control)
and heparin binding region (mAb A32, 50.3 ± 9.0% loss versus con-
trol) was observed after exposure of the ﬁbronectin to the MPO/Cl−/
H2O2 system. The presence of increasing concentrations of I− resulted
in a decreased loss of epitope recognition to levels of ca. 90% for both
antibodies, with this being statistically-signiﬁcant for 1–100 μM I−. The
small decrease in antibody recognition at very high I− concentrations
(50–100 μM) was not statistically signiﬁcant.
The formation of modiﬁed epitopes on ﬁbronectin was probed with
mAb 2D10G9 which recognises HOCl-modiﬁed proteins [25,26,60–62].
Untreated ﬁbronectin, BSA and HSA (used as controls) showed only
very low background signals. After exposure to the MPO/Cl−/H2O2
system, the oxidant-treated samples showed signiﬁcant recognition by
2D10G9, consistent with signiﬁcant HOCl-mediated damage (Fig. 1C).
The presence of increasing concentrations of I− resulted in decreased
recognition by 2D10G9, consistent with lower extents of damage, with
this being signiﬁcant at I− concentrations> 0.1 μM. Whilst 2D10G9
also recognise HOBr-induced damage [34], the current results suggest
that this antibody does not recognise HOI-mediated protein damage,
though the exact epitope recognised by this antibody is poorly deﬁned
[25,34].
3.2. Structural changes to human ﬁbronectin induced by the MPO/Cl−/
H2O2 system in the presence of I−
In order to investigate the eﬀect of I− upon MPO-mediated changes
in protein structure, ﬁbronectin (1 μM) was treated with MPO (0.1 μM)/
H2O2 (500 μM)/Cl− (100mM) in the absence or presence of varying
concentrations of I− (0–400 μM). Eﬀects on ﬁbronectin structure were
probed by SDS-PAGE followed by immunoblotting. In the presence of
MPO/H2O2/Cl−, additional bands were detected by immunoblotting
using mAb A17, at masses higher and lower that the parent protein
ﬁbronectin, which appears as a single broad band due to the similarity
in masses of the two (α and β) chains under reducing conditions (c.f.
lanes 1 vs. 12 in Fig. 2). The presence of low concentrations of I−
(0.01–0.5 μM) did not give rise to signiﬁcant changes (Fig. 2), whereas
with higher I− levels (1–5 μM) a small decrease in the intensity of
staining of both the higher and lower mass bands were detected, to-
gether with a more intense staining of the parent protein band. At very
high concentrations of I− ( > 100 μM) a marked increase in ﬁ-
bronectin fragmentation and aggregation was detected, together with a
loss of recognition of the parent protein band. These changes are con-
sistent with a reduction in protein damage at low I− concentrations,
and a higher extent of modiﬁcation with very high levels of I−. The
presence of protein bands at ca. 460 kDa is consistent with the forma-
tion of ﬁbronectin homo- and hetero-dimers (α-α, β-β, α-β). As these
samples were analysed under reducing conditions, these higher mole-
cular mass species are unlikely to be disulﬁde-bonded species. Protein
samples prepared and separated under identical conditions, and probed
using an antibody against di-tyrosine, did not give positive staining,
suggesting that these aggregates do not arise via the formation of this
particular cross-link (data not shown). The identity of the cross-links
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Fig. 1. ELISA based detection of HOCl-mediated damage to human plasma ﬁbronectin incubated with a MPO/H2O2/Cl− system, in the absence or presence of I−.
Antibodies were used to detect (A) damage to the cell-binding fragment (anti-ﬁbronectin mAb A17), (B) damage to the heparin-binding region (anti-ﬁbronectin mAb
A32), and (C) HOCl-induced damage (mAb 2D10G9, raised against HOCl-modiﬁed protein). Human plasma ﬁbronectin (2.5 μg in 50 μL) was treated with MPO
(20 nM), H2O2 (32 μM), Cl− (100 mM) for 2 h at 37 °C in 0.1 M phosphate buﬀer, pH 7.4. Data are presented as mean + SD from 3 independent experiments. #
Indicates statistical signiﬁcance of the control against the oxidized sample in the absence of I− (0 μM I−) as determined by Student's t-test. * Indicates statistical
signiﬁcance against the oxidized sample in the absence of I− (0 μM I−), as determined by one-way ANOVA with post-hoc analysis using Dunnett's multiple com-
parison test.
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therefore remains unresolved, though these are likely to be carbon-
carbon linked dimers.
3.3. Quantiﬁcation of amino acid oxidation and 3-chlorotyrosine formation
on ﬁbronectin induced by MPO/Cl−/H2O2 in the presence of varying
concentrations of I−
The eﬀect of increasing I− concentrations on MPO-mediated oxi-
dation of amino acids present on ﬁbronectin was investigated using
UPLC analysis of hydrolysed ﬁbronectin samples. Fibronectin (25 μg in
50 μL 0.1 M phosphate buﬀer) was incubated with MPO/Cl−/H2O2 (as
described above) in the absence and presence of varying concentrations
of I−, prior to total amino acid analysis. In the absence of I−, the levels
of Met and Trp were decreased, relative to the untreated protein, on
exposure to MPO/Cl−/H2O2. All other amino acid residues examined
were not signiﬁcantly aﬀected. In the presence of increasing levels of I−
the loss of Met was decreased in a dose-dependent manner, with this
being statistically signiﬁcant at> 10 μM I− (Fig. 3). No signiﬁcant
change was detected for Trp, though a trend towards a decreased loss
was apparent (Fig. 3). While no signiﬁcant loss of Tyr was detected with
MPO/Cl−/H2O2 in the absence of I−, the presence of high concentra-
tions of this ion (200–400 μM) resulted in a statistically-signiﬁcant
decrease of this amino acid.
We have recently shown that human plasma ﬁbronectin is readily
modiﬁed by MPO-derived HOCl and results in signiﬁcant chlorination
of the protein at Tyr residues, giving both 3-chloroTyr (3-ClTyr) and
3,5-dichloroTyr [58]. Consequently the absolute concentrations of 3-
ClTyr formed on both ﬁbronectin and BSA (as a positive control and for
comparison with previous data) were determined in both the absence
and presence of increasing I− concentrations, using LC-MS. The levels
of 3-ClTyr were markedly elevated on both proteins on treatment with
MPO/Cl−/H2O2 in the absence of I−, with the levels detected on BSA
(ca. 450 nM, 6.5 nmol mg−1 protein) consistent with previous data
[44,63]. Higher levels were detected on ﬁbronectin (ca. 3 μM,
31 nmol mg−1 protein). The presence of I− in both the ﬁbronectin and
BSA systems decreased 3-ClTyr levels in a dose-dependent manner, with
the decrease statistically-signiﬁcant at≥ 10 μM I− (Fig. 4). These data
are consistent with the mAb 2D10G9 antibody studies (Fig. 1C).
3.4. I− improves adhesion of human coronary artery endothelial cells
(HCAECs) to oxidized ﬁbronectin in the MPO/Cl−/H2O2 system
Previous data indicate that human coronary artery endothelial cells
(HCAEC) adhere less well to HOCl-modiﬁed ﬁbronectin when com-
pared to native ﬁbronectin, and also have altered gene expression in
response to the modiﬁed protein [59]. Consequently, cell adhesion as-
says were performed to test whether the presence of I− in the MPO/
H2O2/Cl− system could decrease the loss of cell adhesion arising from
HOCl-induced modiﬁcation. Treatment of ﬁbronectin with the MPO/
Cl−/H2O2 system in the absence of I− resulted in decreased HCAEC
adhesion (60 ± 1.9% relative to non-oxidized control). The presence
of low concentrations of I− decreased this loss of function in a dose-
dependent manner, with this being statistically signiﬁcant at ≥ 1 μM
(Fig. 5).
3.5. Myeloperoxidase activity is perturbed by high concentrations of I−
The data presented above indicate that I− at low concentrations can
reduce the extent of damage induced by MPO/H2O2/Cl− reaction sys-
tems. One potential rationale for these eﬀects is potential (reversible or
irreversible) inhibition of the MPO catalytic cycle, or by other sec-
ondary reactions involving I−. In order to test these possibilities, the
catalytic turnover of MPO was quantiﬁed, as measured by H2O2 con-
sumption (using a H2O2-sensitive electrode) in the presence of Cl−
(100mM), Met (250 μM, as a scavenger for HOCl to prevent enzyme
auto-inactivation), and the absence and presence of increasing con-
centrations of I−. H2O2 (50 μM) was introduced into a phosphate-buf-
fered solution containing Cl− (100mM) and I− (0, 1, 10, 25, 100 μM),
and the reaction initiated by the addition of MPO (20 nM). Under these
conditions the formation of Compound I, by reaction of the native en-
zyme with the added H2O2 is rapid, and the turnover of the enzyme is
limited by the reaction of Compound I with Cl− or I−. No direct re-
action between H2O2 and I− was observed prior to the addition of MPO.
In the absence of I−, H2O2 was consumed at a rate of 3.5 μMmin−1
Fig. 2. Structural changes induced on human plasma
ﬁbronectin induced by incubation with a MPO/
H2O2/Cl− system in the presence of I−, detected by
Western-blot following SDS-PAGE separation under
reducing conditions. The blot was probed for re-
cognition of the cell-binding region of ﬁbronectin
using anti-Fibronectin mAb A17 and subsequent
chemiluminescence detection (see Materials and
Methods). The major bands detected are from the
monomer bands of ﬁbronectin. A representative blot
is presented.
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Fig. 3. UPLC quantiﬁcation of (A) Met, (B) Trp, (C) Tyr and (D) Phe on human plasma ﬁbronectin (5.68 μM) following treatment with MPO/H2O2/Cl− in the absence
or presence of I−. Human plasma ﬁbronectin (25 μg in 50 μL, 1.14 μM) was treated with MPO (100 nM), H2O2 (500x excess, 570 μM), Cl− (100mM) in the absence or
presence of increasing I− (0–400 μM) for 2 h at 37 °C in 0.1 M phosphate buﬀer, pH 7.4. Data are presented as mean + SD of three independent experiments. #
Indicates statistical signiﬁcance of the control against the oxidized sample in the absence of I− (0 μM I−) as determined by Student's t-test. * Indicates statistical
signiﬁcance against the oxidized sample in the absence of I− (0 μM I−) as determined by one-way ANOVA with post-hoc analysis using Dunnett's multiple com-
parison test.
Fig. 4. Quantiﬁcation of 3-ClTyr on (A) BSA, and (B) human plasma ﬁbronectin, following treatment with MPO/H2O2/Cl− in the presence of I−. BSA or human
plasma ﬁbronectin (25 μg in 50 μL, 1.14 μM) were incubated with MPO (100 nM), H2O2 (500x excess, 570 μM), Cl− (100mM) in the absence or presence of
increasing concentrations of I− (0–400 μM) for 2 h at 37 °C in 0.1 M phosphate buﬀer, pH 7.4, before analysis by LC-MS. Data are presented as mean + SD from three
independent experiments. # Indicates statistical signiﬁcance of the control against the oxidized sample in the absence of I− (0 μM I−) as determined by Student's t-
test. * Indicates statistical signiﬁcance against the oxidized sample in the absence of I− (0 μM I−) as determined by one-way ANOVA with post-hoc analysis using
Dunnett's multiple comparison test.
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(Fig. 6) The presence of low concentrations of I− did not signiﬁcantly
perturb this rate, with only concentrations of I− ≥ 25 μM, found to
signiﬁcantly enhance the turnover of MPO, with consumption rates of
5.7 and 7.5 μMmin−1 detected at 25 and 100 μM respectively (Fig. 6).
3.6. Determination of iodate (IO3−) formation by the MPO/Cl−/H2O2
system
As MPO does not appear to be signiﬁcantly inhibited by low con-
centrations of I−, the potential formation of iodate (IO3−), a known
oxidation product of I−, was examined and quantiﬁed, as well as the
potential perturbation of MPO activity by this species. Previous studies
have postulated that reaction of I− with either the MPO/H2O2/Cl−
system, or its product HOCl, forms HOI and hence IO3− via a rapid
disproportionation reaction that regenerates a proportion of the I−
originally consumed (Equation (2)) [64]. These secondary products,
such as IO3−, would be expected to be less reactive than HOI itself [65].
The formation of IO3− on reaction of HOCl with I− was conﬁrmed by
spectrophotometric assay after reaction of HOCl (100 μM) with equi-
molar concentrations of I− at 21 °C over a period of 20min (Table 1).
Under these conditions HOCl should be converted rapidly to HOI which
will undergo moderately slow (quantitative) disproportionation to I−
and IO3− (Equations (1) and (2)) [64,66]. The concentration of IO3−
detected was ca. 33 μM, consistent with the expected value of 33 μM
predicted from this chemistry.
+ → +
− −HOCl I HOI Cl (1)
→ + +
− − +3HOI IO 2I 3H3 (2)
IO3− generation was also examined after incubation of MPO with
H2O2 (100 μM), Cl− (100mM) and I− (100 μM) at 37 °C over a period
of 2 h. The concentration of IO3− detected was below the limit of de-
tection of the assay (2 μM) in both the absence and presence of 50 nM
BSA (as a potential target for IO3−). Subsequent bolus addition of HOCl
(100 μM) to these reactions, to oxidize any residual I−, resulted in the
detection of ca. 34 μM IO3− in both the absence and presence of BSA
(Table 1). These data suggest that most of the initial I− is not converted
Fig. 5. Adhesion of human coronary artery endothelial cells (HCAECs) to ﬁ-
bronectin pretreated with a MPO/H2O2/Cl− system in the absence or presence
of I−. Human plasma ﬁbronectin (2.5 μg in 50 μL) was coated onto a 96-well
plate and treated with MPO (20 nM), H2O2 (32 μM), Cl− (100mM) for 2 h at
37 °C in 0.1M phosphate buﬀer, pH 7.4. Wells were washed with DPBS and
blocked with 1% denatured-BSA in DPBS. HCAECs pre-stained with Calcein-AM
(5 μM) were added and allowed to adhere for 2 h. Non-adherent cells were then
removed by centrifugation at 40g for 5 min. Adherent cells were subsequently
quantiﬁed by ﬂuorescence of the Calcein-AM dye as described in the Materials
and methods. Data are presented as mean + SD from three independent ex-
periments. # Indicates statistical signiﬁcance of the control against the oxidized
sample in the absence of I− (0 μM I−) as determined by Student's t-test. *
Indicates statistical signiﬁcance against the oxidized sample in the absence of
I− (0 μM I−) as determined by one-way ANOVA with post-hoc analysis using
Dunnett's multiple comparison test.
Fig. 6. Consumption of H2O2 over time detected using a H2O2-sensitive electrode (HPO-ISO-2) in the absence and presence of the MPO system in the absence or
presence of the indicated concentrations of I−. MPO (20 nM) was spiked into a solution of Cl− (100mM) and H2O2 (50 μM) in 0.1M sodium phosphate buﬀer at pH
7.4. Reactions were performed at 25 °C. Panel (A) shows representative time course data (from 3 independent experiments) for H2O2 consumption. Panel (B) shows
the rate of H2O2 consumption as determined by the slope of the curve over the ﬁrst 120 s following stabilization of the signal after injection of MPO. Data in panel (B)
are presented as mean + SD from 3 independent experiments, with * indicating statistical signiﬁcance against the oxidized sample in the absence of I− (0 μM I−) as
determined by one-way ANOVA with post-hoc analysis using Dunnett's multiple comparison test.
Table 1
Quantiﬁcation of iodate (μM) generated from reagent HOCl or HOCl generated
by the MPO system in the absence and presence of I− and BSA. HOCl was
generated through reaction of MPO (100 nM), H2O2 (100 μM), I− (100 μM) and
Cl− (100mM) for 2 h at 37 °C in 0.1M phosphate buﬀer, pH 7.4, with or
without BSA (50 nM). Presence of I− in the reaction mixture was conﬁrmed by
addition of HOCl (100 μM) and quantiﬁcation of IO3− (via disproportionation
of HOI). The determination of IO3− was performed by spectrophotometric
assay with an excess of KI under acidic conditions. Data are presented as
mean ± SD of three experimental replicates. LOD: limit of detection.
*Theoretical yield: 33 μM.
Oxidation system Concentration of IO3− detected/μM
I− alone MPO + H2O2 + I− + Cl−
−BSA −BSA +BSA
−HOCl < 2 (LOD) <2 (LOD) <2 (LOD)
+HOCl 33.0 ± 0.6 * 33.7 ± 0.2 33.7 ± 0.5
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to IO3−, or other products, during incubation with MPO/H2O2/Cl−.
As IO3−, even if formed at low levels, might act as an MPO in-
hibitor, the activity of MPO was examined by determining the yield of
chloramines formed from added taurine, by HOCl, using the TNB assay
[56]. The yield of taurine chloramines was not perturbed by the pre-
sence of IO3−, at concentrations up to 40 μM, indicating that IO3− is
not a signiﬁcant inhibitor of MPO activity (Fig. 7).
4. Discussion
Multiple studies have demonstrated an association between MPO
levels and outcomes of cardiovascular disease, with high levels in-
dicative of poor health outcomes [67]. Previous work has shown that
SCN− can reduce the extent of MPO-induced damage on BSA and
human plasma proteins, as judged by Met oxidation and 3-ClTyr for-
mation, even in the presence of high Cl− concentrations [44]. Other
studies have also shown that damage to ﬁbronectin can be attenuated
by SCN− [13], and that this anion can prevent damage in animal
models of disease including cystic ﬁbrosis and atherosclerosis
[45,68,69]. Here we have examined whether I−, another high aﬃnity
substrate for MPO, behaves in a similar manner, as I− levels can be
readily elevated in animals and humans by simple interventions. Such
an activity might therefore have signiﬁcant health beneﬁts, and be
readily applied.
Exposure of plasma ﬁbronectin to HOCl and MPO/H2O2/Cl− in-
duces protein damage in a dose-dependent manner [58,59]. The re-
sidues modiﬁed by such exposure have been characterized by UPLC and
MS peptide mass mapping, and include Tyr, Trp, His, Met and Cys/
cystine [58]. Some of these modiﬁcations occur within functional (cell-
and heparin-binding) domains, consistent with the loss of native epi-
topes, and altered functional properties including its capacity to act as a
substrate for cell adherence and proliferation [58,59].
In the current study it has been demonstrated that such damage can
be ameliorated by I− at concentrations as low as 1 μM, with these low
concentrations providing protection against modiﬁcation to both the
cell-binding and heparin-binding domains (Fig. 1A and B). Further-
more, the loss of cell adhesion to ﬁbronectin induced by MPO/H2O2/
Cl− was also attenuated by low concentrations of I− (Fig. 3).
Previous studies have shown that HOCl can modify the structure of
ﬁbronectin [59], with dose-dependent aggregation and fragmentation
detected by SDS-PAGE with silver staining, and use of mAb A17 against
the cell-binding epitope. In contrast, the data presented here indicate
that the species formed by the MPO/H2O2/Cl− system in the presence
of I−, did not give rise to marked cross-linking or fragmentation of the
protein, except at extremely high concentrations of I−. Under the latter
conditions signiﬁcant smearing of the protein bands was detected to
both lower and higher molecular masses, with the latter being parti-
cularly marked. These data indicate that HOI, the likely initial product
of I− oxidation, does not induce dramatic eﬀects on the protein struc-
ture when formed at modest concentrations. In contrast, molecular io-
dine (I2) or I3−, which may be formed from I− by HOI at high con-
centrations, may be the source of these changes, with this occurring via
iodination of Tyr (and possibly other residues) and cross-linking (pos-
sibly di-Tyr formation) (cf. the reactions of thyroid peroxidase) [70,71].
There is no evidence for the presence of such high I− concentrations
( > 100 μM; Fig. 2) at sites in inﬂammation, though they may occur in
extreme cases of I− overdoses. Even in the thyroid gland, where I− is
concentrated (to levels 20–50 times higher than those of plasma
[72,73]) and used by thyroid peroxidase to iodinate thyroglobulin [70],
these levels are below these that induce marked ﬁbronectin damage.
Amino acids represent a major target for HOCl [74]. Under our
conditions, most of the amino acids present in ﬁbronectin were un-
aﬀected by the MPO/H2O2/Cl− system, both in the absence and pre-
sence of I−. The data obtained in the absence of I− are in accord with
previous reports for HOCl and MPO/H2O2/Cl−, with stable (long-lived)
modiﬁcations limited to Met, Cys/cystine, Trp, Tyr and His [58,59].
Reaction at amines, such as the ε-amino group of Lys side-chains, occurs
at modest rates, but this yields unstable chloramines (RNHCl) [75],
which would not be detected under the conditions used in these ana-
lyses. In the current study, oxidation of Met by the MPO/H2O2/Cl−
system was decreased in a dose-dependent manner by I−. In contrast to
previous and current MS studies (see above and below), no signiﬁcant
loss of Tyr was detected by UPLC, probably due to the insensitivity of
this method at low levels of modiﬁcation. However a small but sig-
niﬁcant loss of Tyr was detected by UPLC with the MPO/H2O2/Cl−
system with high I− concentrations in agreement with previous data on
the iodination of Tyr residues by peroxidases (Fig. 4A) [70].
The MS analyses showed signiﬁcant formation of 3-ClTyr induced
by MPO/H2O2/Cl−on both ﬁbronectin and the model protein BSA, with
the levels of this biomarker decreased in a dose-dependent manner by
increasing I− concentrations. HOCl-mediated damage recognised by
the mAb 2D10G9 (raised against HOCl-damaged low-density lipopro-
teins) was also signiﬁcantly reduced in the presence of I−, as de-
termined by ELISA assay. As previous studies have shown that 3-ClTyr
levels correlate with the severity of chronic kidney damage and cardi-
ovascular disease [76], modulation of the formation of this biomarker
may be of clinical signiﬁcance.
Fibronectin and MPO have been shown previously to colocalise in
diseased tissue [59], and MPO has also been shown to colocalise with
HOCl-modiﬁed proteins in atherosclerotic plaques [34,77]. Further-
more, proteins immunoprecipitated with mAb 2D10G9 (i.e. species
damaged by HOCl) have been shown to be recognised by ﬁbronectin
antibodies and to migrate on gels at the expected masses for ﬁbronectin
chains, consistent with ﬁbronectin modiﬁcation by MPO/H2O2/Cl− in
human atherosclerotic lesions [59]. Increased I− levels in vivo may
therefore reduce the amount of tissue damage induced by MPO. These
results provide a novel mechanism which rationalizes the improved
outcomes observed in animals (mice, rats and pigs) administered I−
prior to induction of an acute myocardial infarction [50,78].
While I− is a high aﬃnity substrate for MPO, the mechanism
through which I− reduces damage to ﬁbronectin (and also BSA) is yet
to be fully elucidated. Although the rate constants for reaction of Cl−
with Compound I of MPO is much lower than that for I−, the high
plasma concentrations of Cl− would be expected to more than com-
pensate for this, and hence with normal physiologic anion concentra-
tions, Cl− would be expected to outcompete I− as a substrate [7]. In the
case of SCN−, the rate constants for reaction of this anion and I− with
Fig. 7. Concentration of chloramine detected on taurine as determined using
the TNB assay (see Materials and methods) after reaction of taurine (40mM)
with MPO (100 nM), H2O2 (50 μM), and Cl− (100mM) in 0.1M sodium phos-
phate buﬀer, pH 7.4, in the absence and presence of varying concentrations of
IO3−. Data are presented as mean + SD from 3 independent experiments. No
statistical signiﬁcance was detected between the samples as assessed by one-
way ANOVA with post-hoc analysis using Dunnett's multiple comparison test.
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Compound I are similar, and therefore the higher concentrations of
SCN− compared to I− in plasma, would also be expected to limit I−
oxidation. These data therefore suggest that competitive reaction of I−
with Compound I may not be the sole factor responsible for the de-
creased damage observed with increasing I− concentrations, assuming
the published rate constants for reactions of Compound I are correct.
A second potential explanation for the observed reduction in da-
mage is via direct oxidation of I− with HOCl, with consequent con-
sumption of the latter (Equation (1)). This reaction is rapid [66] and
hence should compete with protein targets for HOCl (cf. k for reaction
with Cys of 3×108M−1 s−1) [79]. However, the data reported here
indicate that statistically-signiﬁcant protection occurs with I− con-
centrations that considerably below the concentrations of HOCl that are
likely to be formed from the H2O2 provided to MPO. Under such con-
ditions, I− would only be expected to remove a limited amount of the
HOCl formed, assuming that the stoichiometry of Equations (1) and (2)
is correct. Thus, each mole of I− would be expected to quench 3mol of
HOCl. Whilst conversion of HOI to IO3−, which is a far weaker oxidant
than either H2O2, HOCl or HOI, might partially account for the sub-
stoichiometric eﬀects, the iodate assay data (Table 1) indicates that
little IO3− is formed on reaction of MPO/H2O2/Cl− with I−, and the
spiking experiments with added HOCl (to convert remaining I− to HOI
and therefore IO3−) reveal that I− is still present at high concentrations
and is not converted to HOI or IO3−. Reactions with BSA provided si-
milar data, indicating there is no signiﬁcant consumption of I− by the
protein. IO3− also had no eﬀect on chloramine formation (a marker of
enzyme activity), consistent with recent observations that, in contrast
to I−, IO3− does not provide a beneﬁt in a mouse model of reperfusion
injury [50]. Our results (Fig. 7) imply that IO3−, even if formed tran-
siently, does not have a signiﬁcant inhibitory eﬀect on MPO. These data
indicate that direct scavenging of HOCl by I− is unlikely to be the major
damaging-limiting pathways, unless other, unknown, recycling reac-
tions occur.
Potential inhibition of MPO activity by I− also does not appear to be
a major process as the concentrations of I− that provide protection to
ﬁbronectin did not signiﬁcantly perturb H2O2 consumption by MPO.
These data therefore suggest that I− does not directly inhibit MPO (e.g.
by binding to and/or blocking the active site). These studies also in-
dicate that direct oxidation of I− by H2O2 is not a signiﬁcant event, as
no loss of H2O2 was observed upon addition of I− in the absence of
MPO; this is consistent with a slow reaction between these materials at
the concentrations used here (Fig. 6A) and also previous data [80].
Interference with the catalytic cycle of MPO, and particularly re-
moval of Compound I via conversion to Compound II via a one-electron
(peroxidase cycle) reaction also appears unlikely, as although I− has a
modest one-electron reduction potential (I·/I−, +1.35 V), this value is
greater than that the one-electron reduction potential of Compound I
(+1.16 V) and hence thermodynamically unfavourable [6,81].
These arguments suggest that, rather than inhibiting the enzyme or
acting as a competitive substrate, I− act in a catalytic manner, via an
unidentiﬁed very fast secondary reaction mechanism. Alternatively, it
may be a more eﬃcient substrate for the enzyme than previously in-
dicated [7]. The precise mechanism giving rise to the observed pro-
tection by low micromolar concentrations of I− therefore warrants
additional study.
Irrespective of the precise mechanism, the data presented here in-
dicate that I− can reduce MPO-induced damage in vitro at concentra-
tions that can be achieved physiologically, with amelioration of protein
damage and loss of cell adhesion detected at I− concentrations as low as
1 μM. This concentration can be readily achieved in humans by oral
supplementation [53], and it is also possible that local in vivo con-
centrations of I− may be higher than systemic values, and may there-
fore result in greater eﬀects than previously suspected. These results
indicate the need for further investigation of I− as a therapeutic agent
and, more speciﬁcally, whether the observed beneﬁts of I− supple-
mentation in cardiovascular disease are a result of interactions with
MPO and its oxidants.
Conﬂicts of interest
The authors declare no conﬂicts of interest with regard to the data
presented.
Acknowledgements
The authors are grateful to the Novo Nordisk Foundation (Grant:
NNF13OC0004294) for ﬁnancial support. LFG gratefully acknowledges
support from the People Programme (Marie Curie Actions) of the
European Union's Seventh Framework Programme (FP7/2007-2013)
under REA grant agreement nº 608765. VS gratefully acknowledges
support from an EU Marie Curie (Grant No. DENOCS H2020-MSCA-IF-
2016-74) Fellowship.
References
[1] M.B. Zimmermann, The role of iodine in human growth and development, Semin.
Cell Dev. Biol. 22 (6) (2011) 645–652.
[2] F. Delange, The Disorders Induced by Iodine Deﬁciency, 4 (1) (1994) 107–128.
[3] M.B. Zimmermann, P.L. Jooste, C.S. Pandav, Iodine-deﬁciency disorders, The
Lancet 372 (9645) (2008) 1251–1262.
[4] M.J. Davies, C.L. Hawkins, D.I. Pattison, M.D. Rees, Mammalian heme peroxidases:
from molecular mechanisms to health implications, Antioxidants Redox Signal. 10
(7) (2008) 1199–1234.
[5] S.J. Klebanoﬀ, Myeloperoxidase: friend and foe, J. Leukoc. Biol. 77 (5) (2005)
598–625.
[6] J. Arnhold, P.G. Furtmuller, G. Regelsberger, C. Obinger, Redox properties of the
couple compound I/native enzyme of myeloperoxidase and eosinophil peroxidase,
Eur. J. Biochem. 268 (19) (2001) 5142–5148.
[7] P.G. Furtmuller, U. Burner, C. Obinger, Reaction of myeloperoxidase compound I
with chloride, bromide, iodide, and thiocyanate, Biochemistry 37 (51) (1998)
17923–17930.
[8] S.J. Nicholls, S.L. Hazen, Myeloperoxidase and cardiovascular disease, Arterioscler.
Thromb. Vasc. Biol. 25 (6) (2005) 1102–1111.
[9] T.M. Jeitner, M. Kalogiannis, B.F. Krasnikov, I. Gomolin, M.R. Peltier, G.R. Moran,
Linking inﬂammation and Parkinson disease: hypochlorous acid generates parkin-
sonian poisons, Toxicol. Sci. 151 (2) (2016) 388–402.
[10] M.J. Davies, Myeloperoxidase-derived oxidation: mechanisms of biological damage
and its prevention, J. Clin. Biochem. Nutr. 48 (1) (2010) 8–19.
[11] B.S. van der Veen, M.P.J. de Winther, P. Heeringa, Myeloperoxidase: molecular
mechanisms of action and their relevance to human health and disease,
Antioxidants Redox Signal. 11 (11) (2009) 2899–2937.
[12] S. Baldus, V. Rudolph, M. Roiss, W.D. Ito, T.K. Rudolph, J.P. Eiserich, K. Sydow,
D. Lau, K. Szocs, A. Klinke, L. Kubala, L. Berglund, S. Schrepfer, T. Deuse,
M. Haddad, T. Risius, H. Klemm, H.C. Reichenspurner, T. Meinertz, T. Heitzer,
Heparins increase endothelial nitric oxide bioavailability by liberating vessel-im-
mobilized myeloperoxidase, Circulation 113 (15) (2006) 1871–1878.
[13] M.D. Rees, L. Dang, T. Thai, D.M. Owen, E. Malle, S.R. Thomas, Targeted sub-
endothelial matrix oxidation by myeloperoxidase triggers myosin II-dependent de-
adhesion and alters signaling in endothelial cells, Free Radic. Biol. Med. 53 (12)
(2012) 2344–2356.
[14] D.I. Pattison, M.J. Davies, Absolute rate constants for the reaction of hypochlorous
acid with protein side chains and peptide bonds, Chem. Res. Toxicol. 14 (10) (2001)
1453–1464.
[15] D.I. Pattison, M.J. Davies, C.L. Hawkins, Reactions and reactivity of myeloperox-
idase-derived oxidants: diﬀerential biological eﬀects of hypochlorous and hy-
pothiocyanous acids, Free Radic. Res. 46 (8) (2012) 975–995.
[16] C.C. Winterbourn, Reconciling the chemistry and biology of reactive oxygen spe-
cies, Nat. Chem. Biol. 4 (5) (2008) 278–286.
[17] A. Nikolaos, D. Spyridon, B. Georgios, G. Georgios, T. Dimitrios, A. Christos,
K. Andreas, S. Christodoulos, Myeloperoxidase: expressing inﬂammation and oxi-
dative stress in cardiovascular disease, Curr. Top. Med. Chem. 13 (2) (2013)
115–138.
[18] A.A. Woods, S.M. Linton, M.J. Davies, Detection of HOCl-mediated protein oxida-
tion products in the extracellular matrix of human atherosclerotic plaques,
Biochem. J. 370 (Pt 2) (2003) 729–735.
[19] S.L. Hazen, J.W. Heinecke, 3-Chlorotyrosine, a speciﬁc marker of myeloperoxidase-
catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from
human atherosclerotic intima, J. Clin. Investig. 99 (9) (1997) 2075–2081.
[20] S.J. Nicholls, L. Zheng, S.L. Hazen, Formation of dysfunctional high-density lipo-
protein by myeloperoxidase, Trends Cardiovasc. Med. 15 (6) (2005) 212–219.
[21] L. Zheng, B. Nukuna, M.-L. Brennan, M. Sun, M. Goormastic, M. Settle, D. Schmitt,
X. Fu, L. Thomson, P.L. Fox, H. Ischiropoulos, J.D. Smith, M. Kinter, S.L. Hazen,
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and
functional impairment in subjects with cardiovascular disease, J. Clin. Investig. 114
(4) (2004) 529–541.
[22] C. Bergt, S. Pennathur, X. Fu, J. Byun, K. O'Brien, T.O. McDonald, P. Singh,
L.F. Gamon, et al. Redox Biology 28 (2020) 101331
10
G.M. Anantharamaiah, A. Chait, J. Brunzell, R.L. Geary, J.F. Oram, J.W. Heinecke,
The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery
wall and impairs ABCA1-dependent cholesterol transport, Proc. Natl. Acad. Sci. U.
S. A. 101 (35) (2004) 13032–13037.
[23] M.J. Chow, R. Turcotte, C.P. Lin, Y. Zhang, Arterial extracellular matrix: a me-
chanobiological study of the contributions and interactions of elastin and collagen,
Biophys. J. 106 (12) (2014) 2684–2692.
[24] H. Ju, I.M. Dixon, Extracellular matrix and cardiovascular diseases, Can. J. Cardiol.
12 (12) (1996) 1259–1267.
[25] H.J. Grone, E.F. Grone, E. Malle, Immunohistochemical detection of hypochlorite-
modiﬁed proteins in glomeruli of human membranous glomerulonephritis, Lab.
Investig. 82 (1) (2002) 5–14.
[26] L.J. Hazell, L. Arnold, D. Flowers, G. Waeg, E. Malle, R. Stocker, Presence of hy-
pochlorite-modiﬁed proteins in human atherosclerotic lesions, J. Clin. Investig. 97
(6) (1996) 1535–1544.
[27] L.J. Hazell, G. Baernthaler, R. Stocker, Correlation between intima-to-media ratio,
apolipoprotein B-100, myeloperoxidase, and hypochlorite-oxidized proteins in
human atherosclerosis, Free Radic. Biol. Med. 31 (10) (2001) 1254–1262.
[28] S.L. Hazen, Myeloperoxidase and plaque vulnerability, Arterioscler. Thromb. Vasc.
Biol. 24 (7) (2004) 1143–1146.
[29] A. Daugherty, J.L. Dunn, D.L. Rateri, J.W. Heinecke, Myeloperoxidase, a catalyst for
lipoprotein oxidation, is expressed in human atherosclerotic lesions, J. Clin.
Investig. 94 (1) (1994) 437–444.
[30] S.J. Nicholls, W.H. Tang, D. Brennan, M.L. Brennan, S. Mann, S.E. Nissen,
S.L. Hazen, Risk prediction with serial myeloperoxidase monitoring in patients with
acute chest pain, Clin. Chem. 57 (12) (2011) 1762–1770.
[31] W.H. Tang, Y. Wu, S.J. Nicholls, S.L. Hazen, Plasma myeloperoxidase predicts in-
cident cardiovascular risks in stable patients undergoing medical management for
coronary artery disease, Clin. Chem. 57 (1) (2011) 33–39.
[32] V. Rudolph, B.U. Goldmann, C. Bos, T.K. Rudolph, A. Klinke, K. Friedrichs, D. Lau,
K. Wegscheider, M. Haddad, T. Meinertz, S. Baldus, Diagnostic value of MPO
plasma levels in patients admitted for suspected myocardial infarction, Int. J.
Cardiol. 153 (3) (2011) 267–271.
[33] I. Rashid, G.J. Maghzal, Y.-C. Chen, D. Cheng, J. Talib, D. Newington, M. Ren,
S.K. Vajandar, A. Searle, A. Maluenda, E.-L. Lindstedt, A. Jabbour, A.J. Kettle,
A. Bongers, C. Power, E. Michaëlsson, K. Peter, R. Stocker, Myeloperoxidase is a
potential molecular imaging and therapeutic target for the identiﬁcation and sta-
bilization of high-risk atherosclerotic plaque, Eur. Heart J. 39 (35) (2018)
3301–3310.
[34] E. Malle, G. Waeg, R. Schreiber, E.F. Gröne, W. Sattler, H.-J. Gröne,
Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in
human atherosclerotic lesions, Eur. J. Biochem. 267 (14) (2001) 4495–4503.
[35] T. Lazarevic-Pasti, A. Leskovac, V. Vasic, Myeloperoxidase inhibitors as potential
drugs, Curr. Drug Metabol. 16 (3) (2015) 168–190.
[36] A.J. Kettle, C.A. Gedye, M.B. Hampton, C.C. Winterbourn, Inhibition of myeloper-
oxidase by benzoic acid hydrazides, Biochem. J. 308 (Pt 2) (1995) 559–563 Pt 2.
[37] A.K. Tiden, T. Sjogren, M. Svensson, A. Bernlind, R. Senthilmohan, F. Auchere,
H. Norman, P.O. Markgren, S. Gustavsson, S. Schmidt, S. Lundquist, L.V. Forbes,
N.J. Magon, L.N. Paton, G.N. Jameson, H. Eriksson, A.J. Kettle, 2-thioxanthines are
mechanism-based inactivators of myeloperoxidase that block oxidative stress
during inﬂammation, J. Biol. Chem. 286 (43) (2011) 37578–37589.
[38] M.D. Rees, S.E. Bottle, K.E. Fairfull-Smith, E. Malle, J.M. Whitelock, M.J. Davies,
Inhibition of myeloperoxidase-mediated hypochlorous acid production by nitr-
oxides, Biochem. J. 421 (1) (2009) 79–86.
[39] M. Koelsch, R. Mallak, G.G. Graham, T. Kajer, M.K. Milligan, L.Q. Nguyen,
D.W. Newsham, J.S. Keh, A.J. Kettle, K.F. Scott, J.B. Ziegler, D.I. Pattison, S. Fu,
C.L. Hawkins, M.D. Rees, M.J. Davies, Acetaminophen (paracetamol) inhibits
myeloperoxidase-catalyzed oxidant production and biological damage at ther-
apeutically achievable concentrations, Biochem. Pharmacol. 79 (8) (2010)
1156–1164.
[40] J. Soubhye, I. Aldib, C. Delporte, M. Prevost, F. Dufrasne, P.V. Antwerpen,
Myeloperoxidase as a target for the treatment of inﬂammatory syndromes: me-
chanisms and structure activity relationships of inhibitors, Curr. Med. Chem. 23
(35) (2016) 3975–4008.
[41] C.J. van Dalen, M.W. Whitehouse, C.C. Winterbourn, A.J. Kettle, Thiocyanate and
chloride as competing substrates for myeloperoxidase, Biochem. J. 327 (Pt 2)
(1997) 487–492.
[42] O. Skaﬀ, David I. Pattison, Michael J. Davies, Hypothiocyanous acid reactivity with
low-molecular-mass and protein thiols: absolute rate constants and assessment of
biological relevance, Biochem. J. 422 (1) (2009) 111–117.
[43] P.E. Morgan, D.I. Pattison, J. Talib, F.A. Summers, J.A. Harmer, D.S. Celermajer,
C.L. Hawkins, M.J. Davies, High plasma thiocyanate levels in smokers are a key
determinant of thiol oxidation induced by myeloperoxidase, Free Radic. Biol. Med.
51 (9) (2011) 1815–1822.
[44] J. Talib, D.I. Pattison, J.A. Harmer, D.S. Celermajer, M.J. Davies, High plasma
thiocyanate levels modulate protein damage induced by myeloperoxidase and
perturb measurement of 3-chlorotyrosine, Free Radic. Biol. Med. 53 (1) (2012)
20–29.
[45] P.E. Morgan, R.P. Laura, R.A. Maki, W.F. Reynolds, M.J. Davies, Thiocyanate
supplementation decreases atherosclerotic plaque in mice expressing human mye-
loperoxidase, Free Radic. Res. 49 (6) (2015) 743–749.
[46] P.E. Nedoboy, P.E. Morgan, T.J. Mocatta, A.M. Richards, C.C. Winterbourn,
M.J. Davies, High plasma thiocyanate levels are associated with enhanced myelo-
peroxidase-induced thiol oxidation and long-term survival in subjects following a
ﬁrst myocardial infarction, Free Radic. Res. 48 (10) (2014) 1256–1266.
[47] J. Arnhold, E. Monzani, P.G. Furtmüller, M. Zederbauer, L. Casella, C. Obinger,
Kinetics and thermodynamics of halide and nitrite oxidation by mammalian heme
peroxidases, Eur. J. Inorg. Chem. 19 (2006) 3801–3811 2006.
[48] S.A. Hoption Cann, Hypothesis: dietary iodine intake in the etiology of cardiovas-
cular disease, J. Am. Coll. Nutr. 25 (1) (2006) 1–11.
[49] H.V. Tran, N.A. Erskine, C.I. Kiefe, B.A. Barton, K.L. Lapane, V.T.H. Do,
R.J. Goldberg, Is low iodine a risk factor for cardiovascular disease in Americans
without thyroid dysfunction? Findings from NHANES, Nutr. Metab. Cardiovasc. Dis.
27 (7) (2017) 651–656.
[50] A. Iwata, M.L. Morrison, M.B. Roth, Iodide protects heart tissue from reperfusion
injury, PLoS One 9 (11) (2014) e112458.
[51] R.A. Matthijsen, D. Huugen, N.T. Hoebers, B. de Vries, C.J. Peutz-Kootstra,
Y. Aratani, M.R. Daha, J.W.C. Tervaert, W.A. Buurman, P. Heeringa,
Myeloperoxidase is critically involved in the induction of organ damage after renal
ischemia reperfusion, Am. J. Pathol. 171 (6) (2007) 1743–1752.
[52] C. Lentner, Geigy Scientiﬁc Tables: Physical Chemistry, Composition of Blood,
Hematology, Somatometric Data, Ciba-Geigy Ltd, Basle, 1984.
[53] D.F. Gardner, R.M. Centor, R.D. Utiger, Eﬀects of low dose oral iodide supple-
mentation on thyroid function in normal men, Clin. Endocrinol. 28 (3) (1988)
283–288.
[54] J.B. Sterling, W.R. Heymann, Potassium iodide in dermatology: a 19th century drug
for the 21st century-uses, pharmacology, adverse eﬀects, and contraindications, J.
Am. Acad. Dermatol. 43 (4) (2000) 691–697.
[55] E. Malle, L. Hazell, R. Stocker, W. Sattler, H. Esterbauer, G. Waeg, Immunologic
detection and measurement of hypochlorite-modiﬁed LDL with speciﬁc monoclonal
antibodies, Arterioscler. Thromb. Vasc. Biol. 15 (7) (1995) 982–989.
[56] C.L. Hawkins, P.E. Morgan, M.J. Davies, Quantiﬁcation of protein modiﬁcation by
oxidants, Free Radic. Biol. Med. 46 (8) (2009) 965–988.
[57] R. Garcia-Arrona, M. Arranz, A. Bordagaray, E. Millán, Practical activity for de-
velopment and validation of a simple UV-spectroscopic method for iodate de-
termination in table salt, J. Lab. Chemical Educ. 5 (2) (2017) 26–31.
[58] T. Nybo, H. Cai, C.Y. Chuang, L.F. Gamon, A. Rogowska-Wrzesinska, M.J. Davies,
Chlorination and oxidation of human plasma ﬁbronectin by myeloperoxidase-de-
rived oxidants, and its consequences for smooth muscle cell function, Redox Biol. 19
(2018) 388–400.
[59] S. Vanichkitrungruang, C.Y. Chuang, C.L. Hawkins, A. Hammer, G. Hoeﬂer,
E. Malle, M.J. Davies, Oxidation of human plasma ﬁbronectin by inﬂammatory
oxidants perturbs endothelial cell function, Free Radic. Biol. Med. 136 (2019)
118–134.
[60] E. Malle, G. Waeg, R. Schreiber, E.F. Grone, W. Sattler, H.J. Grone,
Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in
human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-
modiﬁed proteins, Eur. J. Biochem. 267 (14) (2000) 4495–4503.
[61] G. Marsche, A. Hammer, O. Oskolkova, K.F. Kozarsky, W. Sattler, E. Malle,
Hypochlorite-modiﬁed high density lipoprotein, a high aﬃnity ligand to scavenger
receptor class B, type I, impairs high density lipoprotein-dependent selective lipid
uptake and reverse cholesterol transport, J. Biol. Chem. 277 (35) (2002)
32172–32179.
[62] A. Hammer, G. Desoye, G. Dohr, W. Sattler, E. Malle, Myeloperoxidase-dependent
generation of hypochlorite-modiﬁed proteins in human placental tissues during
normal pregnancy, Lab. Investig. 81 (4) (2001) 543–554.
[63] T. Nybo, S. Dieterich, L.F. Gamon, C.Y. Chuang, A. Hammer, G. Hoeﬂer, E. Malle,
A. Rogowska-Wrzesinska, M.J. Davies, Chlorination and oxidation of the extra-
cellular matrix protein laminin and basement membrane extracts by hypochlorous
acid and myeloperoxidase, Redox Biol. 20 (2019) 496–513.
[64] T.R. Thomas, D.T. Pence, R.A. Hasty, The disproportionation of hypoiodous acid, J.
Inorg. Nucl. Chem. 42 (2) (1980) 183–186.
[65] J. Li, J. Jiang, Y. Zhou, S.-Y. Pang, Y. Gao, C. Jiang, J. Ma, Y. Jin, Y. Yang, G. Liu,
L. Wang, C. Guan, Kinetics of oxidation of iodide (I–) and hypoiodous acid (HOI) by
peroxymonosulfate (PMS) and formation of iodinated products in the PMS/I–/NOM
system, Environ. Sci. Technol. Lett. 4 (2) (2017) 76–82.
[66] Y. Bichsel, U. von Gunten, Oxidation of iodide and hypoiodous acid in the disin-
fection of natural waters, Environ. Sci. Technol. 33 (22) (1999) 4040–4045.
[67] R.K. Schindhelm, L.P. van der Zwan, T. Teerlink, P.G. Scheﬀer, Myeloperoxidase: a
useful biomarker for cardiovascular disease risk stratiﬁcation? Clin. Chem. 55 (8)
(2009) 1462–1470.
[68] J.D. Chandler, B.J. Day, Biochemical mechanisms and therapeutic potential of
pseudohalide thiocyanate in human health, Free Radic. Res. 49 (6) (2015) 695–710.
[69] J.D. Chandler, E. Min, J. Huang, C.S. McElroy, N. Dickerhof, T. Mocatta,
A.A. Fletcher, C.M. Evans, L. Liang, M. Patel, A.J. Kettle, D.P. Nichols, B.J. Day,
Antiinﬂammatory and antimicrobial eﬀects of thiocyanate in a cystic ﬁbrosis mouse
model, Am. J. Respir. Cell Mol. Biol. 53 (2) (2015) 193–205.
[70] B. Di Jeso, P. Arvan, Thyroglobulin from molecular and cellular biology to clinical
endocrinology, Endocr. Rev. 37 (1) (2016) 2–36.
[71] P.J. O'Brien, Peroxidases, Chem. Biol. Interact. 129 (1–2) (2000) 113–139.
[72] N. Carrasco, Iodide transport in the thyroid gland, Biochim. Biophys. Acta 1154 (1)
(1993) 65–82.
[73] B.A. Rousset, How iodide reaches its site of utilisation in the thyroid gland; in-
volvement of solute carrier 26A4 (pendrin) and solute carrier 5A8 (apical iodide
transporter), Eur. Endocrinol. 1 (2007) 81–82.
[74] Michael J. Davies, Protein oxidation and peroxidation, Biochem. J. 473 (Pt 7)
(2016) 805–825.
[75] E.L. Thomas, M.B. Grisham, M.M. Jeﬀerson, Preparation and characterization of
chloramines, Methods Enzymol. 132 (1986) 569–585.
[76] F. Afshinnia, L. Zeng, J. Byun, C.A. Gadegbeku, M.C. Magnone, C. Whatling,
B. Valastro, M. Kretzler, S. Pennathur, Myeloperoxidase levels and its product 3-
chlorotyrosine predict chronic kidney disease severity and associated coronary
L.F. Gamon, et al. Redox Biology 28 (2020) 101331
11
artery disease, Am. J. Nephrol. 46 (1) (2017) 73–81.
[77] S. Baldus, J.P. Eiserich, M.-L. Brennan, R.M. Jackson, C.B. Alexander, B.A. Freeman,
Spatial mapping of pulmonary and vascular nitrotyrosine reveals the pivotal role of
myeloperoxidase as a catalyst for tyrosine nitration in inﬂammatory diseases, Free
Radic. Biol. Med. 33 (7) (2002) 1010–1019.
[78] M.L. Morrison, A. Iwata, C.C. Keyes, W. Langston, M.A. Insko, L.A. Langdale,
M.B. Roth, Iodide improves outcome after acute myocardial infarction in rats and
pigs, Crit. Care Med. 46 (11) (2018).
[79] C. Storkey, M.J. Davies, D.I. Pattison, Reevaluation of the rate constants for the
reaction of hypochlorous acid (HOCl) with cysteine, methionine, and peptide de-
rivatives using a new competition kinetic approach, Free Radic. Biol. Med. 73
(2014) 60–66.
[80] G.T.F. Wong, L.-S. Zhang, The kinetics of the reactions between iodide and hy-
drogen peroxide in seawater, Mar. Chem. 111 (1) (2008) 22–29.
[81] A. Armstrong David, E. Huie Robert, H. Koppenol Willem, V. Lymar Sergei,
G. Merényi, P. Neta, B. Ruscic, M. Stanbury David, S. Steenken, P. Wardman,
Standard electrode potentials involving radicals in aqueous solution: inorganic ra-
dicals (IUPAC Technical Report), Pure Appl. Chem. (2015) 1139.
L.F. Gamon, et al. Redox Biology 28 (2020) 101331
12
